What Vara does

Vara (legal entity MX Healthcare GmbH) is a Berlin-based, venture-backed health AI company founded in 2018 that builds clinically validated, CE-marked (Class IIb under EU MDR) artificial intelligence for breast cancer screening. Its core product is an independent second reader for both screening and diagnostic mammography (2D and 3D tomosynthesis), built on a "decision referral" architecture that combines automatic normal triage, a Safety Net for potentially missed findings, and unclassified case handling that defers to radiologist judgment. The platform is offered as a SaaS/enterprise subscription delivered either as a PACS-integrated Vara Plugin or as the web-based Vara Workflow platform for screening programmes, with continuous performance monitoring and quarterly clinical review tied to cancer registry outcomes.

Vara generates revenue through annual, quote-based B2B enterprise subscriptions sold to national screening programmes, hospital radiology departments, and radiology groups. Go-to-market is a hybrid direct enterprise field sales motion (used to land large screening programmes such as Germany's national mammography screening programme, where Vara supports 50–60% of organised screening) combined with distribution partnerships (DeepC, Sectra Amplifier, Quibim, Medical Horizons) that resell the platform across more than 10 European countries. Customer segments are healthcare-provider led — radiologists, screening programmes, policymakers/health authorities, and hospital IT — with regulatory validation, peer-reviewed clinical evidence, and seamless PACS integration positioned as the primary purchase drivers.

The company has built its commercial position around the PRAIM study (approximately 460,000 women, published in Nature Medicine), which underpins regulatory approvals and marketing claims including a 17.6% improvement in cancer detection rate, up to 80% of normal cases pre-reported, an 84% workload reduction in programme-level configuration, and a Safety Net that detected 20.5% of cancers missed by radiologists. Leadership is co-founder led (Jonas Muff, CEO; Stefan Bunk, CTO) with functional depth across regulatory, product, software, sales, partnerships, and finance, and the company is headquartered at the Merantix AI Campus in Berlin.

Name

Vara

Legal name

MX Healthcare GmbH

Website

https://vara.ai

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Vara is a Berlin-based health AI company that builds CE-marked (Class IIb) independent second-reader software for breast cancer screening, selling enterprise subscriptions to radiologists, hospitals, and national screening programmes across Europe.

Ownership category

akta.pro rank

Product category

Medical Imaging AI / Radiology AI Software

NAICS

Software Publishers (513210), Computer Systems Design and Related Services (54151)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)

akta.pro secondary industries

Mammography & Breast Imaging Systems (HLAHABAF), Imaging Informatics & Workflow (PACS/RIS/VNA) (HLAHABAI), Teleradiology Platforms & Reading Workflow (HLACALAK), Radiology Reporting, Dictation & Structured Reporting (HLACALAF)

Keywords

• AI mammography screening
• Breast cancer detection
• Radiology workflow software
• Medical imaging AI
• Clinical decision support

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. SaaS/Software Subscription: Cloud-based AI analysis platform deployed via PACS integration or Vara platform. Revenue generated through subscription/licensing model to healthcare systems, screening programmes, and hospitals.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Vara develops and sells a CE-marked Class IIb AI software platform that analyses 2D mammograms and 3D digital breast tomosynthesis images to assist radiologists in breast cancer screening. The platform operates as an independent second reader, combining normal-case triage, a Safety Net that flags potentially missed findings, and automated reporting, and is delivered either as a PACS-integrated plugin or as a web-based workflow platform to hospitals and national/regional screening programmes.

Product overview

Vara offers a unified AI platform for breast cancer screening consisting of the core Vera AI engine and multiple integrated modules. The core Vera AI provides independent second reading capability (CE-marked Class IIb) for both screening and diagnostic mammography. Two deployment options exist: Vera Workflow (web-based platform with AI-driven prioritization, safety net alerts, normal triage, and automated reporting) and Vera Plugin (lightweight PACS-integrated solution with fast image analysis). The product portfolio has expanded from 2D mammography to include Vera Tomosynthesis (DBT) for 3D imaging, with the same CE-marked report and PACS integration. Continuous monitoring services ensure ongoing clinical safety through real-time performance tracking and quarterly review sessions.

Differentiator

Problem solved

Functional benefit

Products and services

• Vara AI (Mammography) CE-marked Class IIb AI platform that analyses 2D mammography images and serves as an independent second reader for both screening and diagnostic mammography, combining normal-case triage, Safety Net alerts, and automated reporting. Sold to hospitals, radiology groups, and national/regional screening programmes.
• Vara Tomosynthesis (DBT) AI for 3D digital breast tomosynthesis that analyses synthetic 2D, slabs, and complete 3D stacks and delivers the same CE-marked report and PACS integration as the 2D product. Sold to hospitals and screening programmes using DBT imaging.
• Vara Workflow Web-based screening programme platform providing AI-driven case prioritisation, safety net alerts, normal triage, automated reporting, consensus support across centres, and dashboards for operational oversight. Sold as an enterprise subscription to screening programmes.
• Vara Plugin Lightweight AI deployment solution that integrates directly into existing PACS systems via API, delivering CAD-SR with lesion scores, sub-30-second image analysis, and comprehensive AI reports. Sold to hospitals and radiology practices that prefer PACS-integrated workflows over a separate platform.
• Vara Continuous Monitoring Subscription monitoring service that tracks AI performance, radiologist-AI interactions, and safety net effectiveness in clinical screening settings, with quarterly review sessions and linkage to cancer registry data. Sold to screening programmes and hospital customers to ensure ongoing clinical safety and accountability.

Quantifiable outcome

• Cancer detection rate improved by 17.6% (6.7 vs 5.7 per 1,000)
• +7 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature7 records

Partnerships

Six partnerships are on record, tiered core and major.

• DeepCcoreChannel Partner/ Reseller/ DistributorMajor distribution partnership for European market expansion. DeepC distributes Vara AI solutions across European screening programmes.
• Sectra AmplifiercoreChannel Partner/ Reseller/ DistributorDistribution partnership through Sectra's integration ecosystem. Sectra Amplifier enables Vara AI to reach more European healthcare customers.
• QuibimcoreChannel Partner/ Reseller/ DistributorDistribution partnership for European market expansion, working alongside other distribution partners to extend Vara's reach.
• Medical HorizonscoreChannel Partner/ Reseller/ DistributorDistribution partnership for European market. Medical Horizons distributes Vara AI solutions to healthcare providers.
• University of LübeckmajorStrategic or Co-development PartnerCollaborated on PRAIM study - the world's largest prospective AI screening study involving approximately 460,000 women. Published in Nature Medicine.
• Mammography Reference Center North (Oldenburg)majorStrategic or Co-development PartnerResearch partnership on interval cancer detection study. Joint authors on peer-reviewed publication in European Journal of Radiology.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Lunit: Lunit (South Korea) develops AI for mammography (Lunit INSIGHT MMG) and DBT, competing directly with Vara in breast imaging AI with similar workflow integration and radiologist-assist positioning. Both target national screening programmes and offer CE-marked triage tools.
• Therapixel: Therapixel (France) offers MammoScreen 2.0, a CE-marked AI for mammography reading assistance, the most direct European competitor to Vara with comparable regulatory positioning, breast imaging focus, and screening programme targeting.
• Volpara Health Technologies: Volpara provides a breast imaging analytics platform (Volpara Scorecard, RiskScore, and Aspen Breast) used by screening programmes and clinics worldwide. It is a direct competitor in breast imaging software, though with more focus on quality/mammography reporting than on AI second reading.
• ScreenPoint Medical: ScreenPoint Medical (Netherlands) offers Transpara, a CE-marked AI decision-support tool for breast imaging (2D and DBT), competing head-to-head with Vara in European screening programmes and offering similar radiologist-assist workflow integration.
• iCAD: iCAD markets ProFound AI for DBT and PowerLook Density Assessment, competing with Vara in breast AI across both 2D and 3D mammography with a US-centric commercial focus and FDA-cleared positioning.
• DeepHealth (RadNet subsidiary): DeepHealth, owned by RadNet, offers Saige-Dx, an FDA-cleared AI for breast cancer detection in DBT, providing a direct competitor in the breast AI second-reader category with a strong US commercial footprint.

Broad incumbents

• Hologic: Hologic is a leading mammography modality vendor (3Dimensions DBT system) and bundles Genius AI detection capabilities with its installed base. As a broad incumbent, it competes with Vara through hardware-software bundling rather than standalone AI sales.
• Siemens Healthineers: Siemens Healthineers offers AI-Rad Companion and broad digital health portfolio including mammography AI. It is a broad incumbent in radiology AI rather than a Vara specialist, with strength via integrated imaging hardware-software suites.
• GE HealthCare: GE HealthCare provides the Edison AI platform and breast imaging products, competing with Vara as a broad imaging incumbent with ability to embed AI into its PACS, modalities, and enterprise imaging solutions.

Others

• Sectra: Sectra provides enterprise PACS and imaging IT across Europe, including the Sectra Amplifier marketplace that distributes Vara AI. It is simultaneously a strategic partner (channel) and a peer in imaging IT, with potential vertical-integration risk over time.

Market position

Strengths5 records

Weaknesses1 record

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/vara-ai
• Xx.com/vara_ai

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds6 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vara